Drug Trial Radar · NCT06190093
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Jan 24, 2024
Primary completion
Nov 7, 2024
Study completion Dec 5, 2024
Sponsor
- Lead sponsor
- Outlook Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Conditions
- Neovascular Age-related Macular Degeneration
- Age-Related Macular Degeneration
- Wet Macular Degeneration
Interventions
bevacizumabBiological
1.25 mg, intravitreal injection
ranibizumabBiological
0.5mg, intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8Time frame: Baseline, 8 weeks
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Arcadia, California
Clinical Site
Bakersfield, California
Clinical Site
Beverly Hills, California
Clinical Site
Huntington Beach, California
Clinical Site
Laguna Hills, California
Clinical Site
Long Beach, California
Clinical Site
Modesto, California
Clinical Site
Oakland, California
Clinical Site
Pasadena, California
Clinical Site
Poway, California
Clinical Site
Sacramento, California
Clinical Site
Colorado Springs, Colorado
Clinical Site
Lakewood, Colorado
Clinical Site
Waterford, Connecticut
Clinical Site
Coral Springs, Florida
Clinical Site
Fort Lauderdale, Florida
Clinical Site
Jacksonville, Florida
Clinical Site
Orlando, Florida
Clinical Site
Stuart, Florida
Clinical Site
Oak Forest, Illinois
Clinical Site
Oak Park, Illinois
Clinical Site
Carmel, Indiana
Clinical Site
Lenexa, Kansas
Clinical Site
Lexington, Kentucky
Clinical Site
Hagerstown, Maryland
Clinical Site
Edina, Minnesota
Clinical Site
Saint Louis Park, Minnesota
Clinical Site
Jackson, Mississippi
Clinical Site
Teaneck, New Jersey
Clinical Site
Albuquerque, New Mexico
Clinical Site
Liverpool, New York
Clinical Site
Oceanside, New York
Clinical Site
Rochester, New York
Clinical Site
Westbury, New York
Clinical Site
Asheville, North Carolina
Clinical Site
Hickory, North Carolina
Clinical Site
Wake Forest, North Carolina
Clinical Site
Winston-Salem, North Carolina
Clinical Site
Edmond, Oklahoma
Clinical Site
Charleston, South Carolina
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.